Trials / Conditions / Squamous Cell Carcinoma of the Oropharynx

Squamous Cell Carcinoma of the Oropharynx

23 registered clinical trials studyying Squamous Cell Carcinoma of the Oropharynx — 7 currently recruiting.

Status	Trial	Sponsor	Phase
Withdrawn	Vorinostat in Combination With Chemoradiation in Locally Advanced HPV Negative HNSCC NCT05608369	Case Comprehensive Cancer Center	Phase 2
Recruiting	Head and Neck Carcinoma Clinical Research Platform for Molecular and Blood-based Biomarkers, Treatment and Out NCT06380686	AIO-Studien-gGmbH	—
Recruiting	HPV DNA-Guided Radiotherapy De-intensification of Head and Neck Squamous Cell Carcinoma NCT05962242	University of Virginia	Phase 2
Recruiting	Identification of Individual Histological and Blood Markers in Patients With Recurrent or Metastatic Upper Aer NCT06061705	Fondation Hôpital Saint-Joseph	N/A
Recruiting	De-Intensification of Postoperative Radiotherapy in Patients With Squamous Cell Carcinoma of the Head and Neck NCT06030440	University of Erlangen-Nürnberg Medical School	Phase 2 / Phase 3
Completed	Prospective Clinical Study to Assess the Safety and Efficacy of Versius, in Transoral Robotic Surgery NCT06112535	CMR Surgical Ltd	N/A
Active Not Recruiting	Testing the Safety of Giving a Standard Dose of Radiation Over a Shorter Period of Time for Patients Who Had S NCT05540899	American College of Radiology	Phase 1
Recruiting	A Phase II Study for p16+ Oropharyngeal Cancer PerSonalized De-escalation Treatment at University of MIchigan NCT05894083	University of Michigan Rogel Cancer Center	Phase 2
Active Not Recruiting	Adjuvant Treatment Deintensification After Transoral Surgery for Human Papillomavirus-Positive Squamous Cell C NCT05119036	Indiana University	N/A
Active Not Recruiting	Safety and Efficacy of APG-157 in Head and Neck Cancer NCT05312710	Aveta Biomics, Inc.	Phase 2
Recruiting	Observational Study of Viral BIOmarkers and microRNAs in Tumors Orofarynx and Occult Tumors Positive for Papil NCT05918510	Regina Elena Cancer Institute	—
Unknown	A Phase II Study of Cemiplimab and ISA101b in Patients With Recurrent/Metastatic HPV16 Positive OPC NCT04398524	ISA Pharmaceuticals	Phase 2
Recruiting	p16+ Oropharyngeal Cancer Radiation Optimization Trial Reducing Elective Treatment Volumes (PROTEcT) NCT04104945	AHS Cancer Control Alberta	N/A
Active Not Recruiting	Evaluation of Tongue Base MucOsectomy & Step sErial Sectioning NCT04151134	Royal Marsden NHS Foundation Trust	—
Completed	Study of Hypoxia Measured in F-Miso PET/Scan and MRI in Patients With Squamous Cells Carcinoma NCT04031534	Centre Henri Becquerel	Phase 2
Unknown	A Randomized Phase 2 Study of Cemiplimab ± ISA101b in HPV16-Positive OPC NCT03669718	ISA Pharmaceuticals	Phase 2
Completed	Cetuximab & Nivolumab in Patients With Recurrent/Metastatic Head & Neck Squamous Cell Carcinoma NCT03370276	H. Lee Moffitt Cancer Center and Research Institute	Phase 1 / Phase 2
Completed	Saliva-based Detection of CD44 NCT03148665	Joseph Califano	—
Completed	A Phase 1 Dose Escalation Study of GC4419 in Combination With Chemoradiation for Squamous Cell Cancer of the H NCT01921426	Galera Therapeutics, Inc.	Phase 1
Terminated	Swallowing, Speech and Quality of Life of Patients With Carcinoma of the Oropharynx NCT02552550	Centre Hospitalier Universitaire de Saint Etienne	—
Withdrawn	Stereotactic Boost for Oropharyngeal Squamous Cell Carcinoma NCT01586182	Dana-Farber Cancer Institute	Phase 1 / Phase 2
Completed	Reduced-intensity Therapy for Oropharyngeal Cancer in Non-smoking HPV-16 Positive Patients NCT01663259	University of Michigan Rogel Cancer Center	N/A
Completed	Long-Term Impact of Human Papillomavirus (HPV) on Quality of Life NCT01181648	Memorial Sloan Kettering Cancer Center	—